Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-05-22
2007-05-22
Shameem, Golam M. M. (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C548S356100, C548S373100, C548S376100
Reexamination Certificate
active
11189659
ABSTRACT:
The selective cyclooxygenase-2 inhibitory drug celecoxib is provided in amorphous form. Also provided is a celecoxib drug substance wherein the celecoxib is present, in at least a detectable amount, as amorphous celecoxib. Also provided is a celecoxib-crystallization inhibitor composite comprising particles of amorphous celecoxib or a celecoxib drug substance of the invention in intimate association with one or more crystallization inhibitors, for example polymers. Also provided is a pharmaceutical composition comprising such a celecoxib-crystallization inhibitor composite and one or more excipients. Also provided are processes for preparing amorphous celecoxib, a celecoxib drug substance of the invention, a celecoxib-crystallization inhibitor composite of the invention, and a pharmaceutical composition of the invention. Also provided is a method of treating a medical condition or disorder in a subject where treatment with a cyclooxygenase-2 inhibitor is indicated, comprising administering, for example orally, a composition of the invention in a therapeutically effective amount.
REFERENCES:
patent: 5466823 (1995-11-01), Talley et al.
patent: 5892053 (1999-04-01), Zhi et al.
patent: 6395300 (2002-05-01), Straub et al.
patent: 6864373 (2005-03-01), Zhuang et al.
patent: 6964978 (2005-11-01), Hageman et al.
patent: WO 00/32189 (2000-07-01), None
patent: WO 00/42021 (2000-07-01), None
ed. S. Budavari, The Merck Index, 12th Edition, Therapeutic Category and Biological Activity Index, (1996), pp. Ther-2 to Ther-3 and Ther-12.
Lieberman et al. (1989), Pharmaceutical Dosage Forms: Tablets, vol. 1, pp. 34-36.
Hageman Michael J.
He Xiaorong
Kararli Tugrul T.
MacKin Lesley A.
Miyake Patricia J.
Ashbrook Charles W.
Fitzsimmons Patricia K.
Pharmacia Corporation (of Pfizer Inc.)
Shameem Golam M. M.
LandOfFree
Solid-state form of celecoxib having enhanced bioavailability does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Solid-state form of celecoxib having enhanced bioavailability, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Solid-state form of celecoxib having enhanced bioavailability will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3738737